Results 71 to 80 of about 2,368 (193)

Respiratory Syncytial Virus Under the Lens of Structure: From Prefusion Stabilization to Next‐Generation Immunotherapies

iNew Medicine, Volume 2, Issue 2, June 2026.
This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng, Qianqian Wang, Jiachen Zhang, Sandra Chiu   +3 more
wiley   +1 more source

Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants

Pediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Marine Tarizzo, Julie Mesinèle, Blandine Prevost, Sophie Denamur, Elora Peulier‐Maitre, Loïc Guillot, Nadia Nathan, Harriet Corvol   +7 more
wiley   +1 more source

Nirsevimab som skydd mot Respiratorisk syncytialvirus (RSV) hos spädbarn : Hur effektivt och säkert är nirsevimab som skydd mot RSV hos friska spädbarn?

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among children and represents a major global health concern. Most RSV cases occur during the RSV season, which is during the cold seasons of the year. The infection often begins as
Awad, Zainab
core   +2 more sources

Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants

Importance: Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations, and preterm infants and those with older siblings are at increased risk.
Lorefice, Aurora, Accomando, Francesco, Valletta, Enrico, Morlupo, Francesco Saverio, Pellegrini, Benedetta, Stella, Marcello, Cocchi, Enrico, Scarpellini, Beatrice, Aricò, Melodie O., Aric\uf2, Melodie O., Vergine, Gianluca, Zannoni, Sara, Bloise, Silvia, Ancora, Gina, Marchetti, Federico   +14 more
core   +1 more source

Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.Research design and methods A cohort model was ...
Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W. Law, Diana Mendes   +9 more
doaj   +1 more source

Reluctance of parents to immunize their children with nirsevimab

Anales de Pediatría (English Edition)
2025
Piñeiro Pérez, Roi, Galán Arévalo, Sonsoles, Risso, Milagros, Hidalgo Montes, Inmaculada, López Escobar, Alejandro   +4 more
openaire   +3 more sources

Nirsevimab (▼Beyfortus®): un nuevo anticuerpo monoclonal para la profilaxis frente al virus respiratorio sincitial [PDF]

, 2023
Farmacologia; Medicaments; Virus respiratori sincicialFarmacología; Medicamentos; Virus respiratorio sincicialPharmacology; Medicines; Respiratory syncytial virusAquest article tracta del medicament nirsevimab, un nou anticòs monoclonal que actua ...

core  

Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy

Vaccines
Background: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants, particularly those with risk factors such as prematurity or chronic diseases.
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie Aricò, Angela Lanzoni, Beatrice Rita Campana, Marta Niceforo, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +1 more source

Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants

The Journal of Clinical Pharmacology
AbstractNirsevimab, a monoclonal antibody with an extended half‐life, is approved for the prevention of respiratory syncytial virus (RSV) disease in all infants in Canada, the EU, Great Britain, and the USA. A population pharmacokinetics (PK) model was built to describe the PK of nirsevimab in preterm and term infants, and to evaluate the influence of ...
Lindsay Clegg, Ed Freshwater, Amanda Leach, Tonya Villafana, Ulrika Wählby Hamrén   +4 more
openaire   +2 more sources

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source